TW202246322A - 包含針對類tnf配體1a(tl1a)之人類化抗體之組合物及其用途 - Google Patents

包含針對類tnf配體1a(tl1a)之人類化抗體之組合物及其用途 Download PDF

Info

Publication number
TW202246322A
TW202246322A TW111105898A TW111105898A TW202246322A TW 202246322 A TW202246322 A TW 202246322A TW 111105898 A TW111105898 A TW 111105898A TW 111105898 A TW111105898 A TW 111105898A TW 202246322 A TW202246322 A TW 202246322A
Authority
TW
Taiwan
Prior art keywords
tl1a
dose
antibody
weeks
fcrn
Prior art date
Application number
TW111105898A
Other languages
English (en)
Chinese (zh)
Inventor
艾利森 駱駱
勞倫 奧蘇奇
馬克 曼寧
羅伯特 沛恩
奧立維爾 勞倫特
珍妮娜 比爾斯柏洛夫
布萊德利 漢克爾
史蒂芬 Ｒ 塔甘
Original Assignee
美商普羅米修斯生物科學股份有限公司
美國錫安山醫學中心
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商普羅米修斯生物科學股份有限公司, 美國錫安山醫學中心 filed Critical 美商普羅米修斯生物科學股份有限公司
Publication of TW202246322A publication Critical patent/TW202246322A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
TW111105898A 2021-02-18 2022-02-17 包含針對類tnf配體1a(tl1a)之人類化抗體之組合物及其用途 TW202246322A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202163150825P 2021-02-18 2021-02-18
US63/150,825 2021-02-18
US202163180892P 2021-04-28 2021-04-28
US63/180,892 2021-04-28
US202163226037P 2021-07-27 2021-07-27
US63/226,037 2021-07-27
US202163285781P 2021-12-03 2021-12-03
US63/285,781 2021-12-03

Publications (1)

Publication Number Publication Date
TW202246322A true TW202246322A (zh) 2022-12-01

Family

ID=82931032

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111105898A TW202246322A (zh) 2021-02-18 2022-02-17 包含針對類tnf配體1a(tl1a)之人類化抗體之組合物及其用途

Country Status (19)

Country Link
US (1) US20240309104A1 (https=)
EP (1) EP4294444A4 (https=)
JP (1) JP2024506940A (https=)
KR (1) KR20230157973A (https=)
AU (1) AU2022223420A1 (https=)
BR (1) BR112023016672A2 (https=)
CA (1) CA3207817A1 (https=)
CL (1) CL2023002424A1 (https=)
CO (1) CO2023011969A2 (https=)
CR (1) CR20230436A (https=)
DO (1) DOP2023000162A (https=)
EC (1) ECSP23070237A (https=)
GE (2) GEAP202416596A (https=)
IL (1) IL305312A (https=)
JO (1) JOP20230185A1 (https=)
MX (1) MX2023009622A (https=)
PE (1) PE20231681A1 (https=)
TW (1) TW202246322A (https=)
WO (1) WO2022178159A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102343212B1 (ko) 2013-03-27 2021-12-23 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
JP2022533956A (ja) 2019-05-14 2022-07-27 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａ患者を選択する方法、システム、およびデバイス
KR20220103721A (ko) 2019-10-24 2022-07-22 프로메테우스 바이오사이언시즈, 인크. Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도
EP4637819A1 (en) * 2022-12-22 2025-10-29 Prometheus Biosciences, Inc. Methods of treating inflammatory diseases with combination of tl1a inhibitors and s1pr inhibitors
WO2024173838A2 (en) * 2023-02-17 2024-08-22 Prometheus Biosciences, Inc. Anti-tl1a antibody compositions and methods of treatment in the bile duct
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法
US12473370B2 (en) 2023-10-03 2025-11-18 Absci Corporation TL1A associated antibody compositions and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3375B1 (ar) * 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
MX388027B (es) * 2013-11-13 2025-03-19 Pfizer Anticuerpos específicos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos.
KR102417687B1 (ko) * 2016-05-09 2022-07-07 브리스톨-마이어스 스큅 컴퍼니 Tl1a 항체 및 그의 용도
MY191324A (en) * 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
JP7332627B2 (ja) * 2018-04-25 2023-08-23 プロメテウス バイオサイエンシーズ，インク． 最適化された抗ｔｌ１ａ抗体
WO2021081365A1 (en) * 2019-10-24 2021-04-29 Prometheus Biosciences, Inc. Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof

Also Published As

Publication number Publication date
CA3207817A1 (en) 2022-08-25
BR112023016672A2 (pt) 2023-11-21
JOP20230185A1 (ar) 2023-08-09
DOP2023000162A (es) 2023-10-15
WO2022178159A1 (en) 2022-08-25
GEAP202316354A (en) 2023-12-25
MX2023009622A (es) 2023-08-28
IL305312A (en) 2023-10-01
CO2023011969A2 (es) 2023-09-29
AU2022223420A1 (en) 2023-09-21
JP2024506940A (ja) 2024-02-15
EP4294444A1 (en) 2023-12-27
CR20230436A (es) 2023-11-01
KR20230157973A (ko) 2023-11-17
EP4294444A4 (en) 2025-04-16
GEAP202416596A (en) 2024-10-28
PE20231681A1 (es) 2023-10-19
US20240309104A1 (en) 2024-09-19
ECSP23070237A (es) 2023-10-31
CL2023002424A1 (es) 2024-01-05

Similar Documents

Publication Publication Date Title
US20240336691A1 (en) Anti-tl1a antibody compositions and methods of treatment in the lung
US20240309104A1 (en) Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
JP6515168B2 (ja) Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法
US20250243289A1 (en) Methods of treating inflammatory diseases with combination of tl1a inhibitors and il23 inhibitors
TWI871367B (zh) 針對類-tnf配體1a(tl1a)之人類化抗體及其用途
WO2023009545A1 (en) Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
KR20250160371A (ko) 항-tl1a 항체 조성물 및 피부 치료 방법
EP4665395A1 (en) Anti-tl1a antibody compositions and methods of treatment in the liver
WO2024186859A2 (en) Anti-tl1a antibody compositions and methods of treatment for sarcoidosis
EP4665767A2 (en) Anti-tl1a antibody compositions and methods of treatment in the bile duct
WO2024173865A2 (en) Anti-tl1a antibody compositions and methods of treatment in the kidney
EP4637819A1 (en) Methods of treating inflammatory diseases with combination of tl1a inhibitors and s1pr inhibitors
EP4646443A1 (en) Methods of treating inflammatory diseases with combination of tl1a inhibitors and integrin inhibitors
WO2024148218A2 (en) Methods of treating inflammatory diseases with combination of tl1a inhibitors and tnf inhibitors
CN117202932A (zh) 治疗肺部的抗tl1a抗体组合物和方法
CN118059231A (zh) 包括针对tnf样配体1a（tl1a）的人源化抗体的组合物以及其用途